Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year Low at $4.82

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) shares reached a new 52-week low during trading on Thursday . The company traded as low as $4.82 and last traded at $4.87, with a volume of 115637 shares. The stock had previously closed at $4.91.

Analyst Ratings Changes

A number of analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, March 1st. Cantor Fitzgerald cut their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Royal Bank of Canada cut their price target on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Finally, Jefferies Financial Group cut their price target on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating for the company in a report on Friday, February 16th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Performance

The company has a market capitalization of $721.64 million, a price-to-earnings ratio of -9.24 and a beta of 1.36. The stock has a fifty day moving average price of $5.49 and a two-hundred day moving average price of $7.27. The company has a quick ratio of 4.99, a current ratio of 5.50 and a debt-to-equity ratio of 0.20.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The business had revenue of $45.10 million during the quarter, compared to analyst estimates of $45.00 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative return on equity of 20.10%. The business’s revenue for the quarter was up 58.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.18) earnings per share. As a group, analysts forecast that Aurinia Pharmaceuticals Inc. will post -0.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Sunbelt Securities Inc. acquired a new position in Aurinia Pharmaceuticals in the first quarter valued at $31,000. Geneos Wealth Management Inc. increased its stake in Aurinia Pharmaceuticals by 54.2% in the first quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,142 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $30,000. China Universal Asset Management Co. Ltd. increased its stake in Aurinia Pharmaceuticals by 95.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,798 shares during the last quarter. Finally, Tidemark LLC acquired a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $39,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.